AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.